Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 3/20 | 0.43 |
| ▸ | DRD2 | P14416 | 12/20 | 0.38 |
| ▸ | DRD4 | P21917 | 12/20 | 0.38 |
| ▸ | DRD3 | P35462 | 12/20 | 0.38 |
| ▸ | DRD1 | P21728 | 11/20 | 0.38 |
| ▸ | HTR2A | P28223 | 11/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | DRD5 | P21918 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3078971 | 0.77 | PIK3CA (0.42) | PIK3CADRD2DRD4DRD3DRD1 | |
| SCHEMBL3064017 | 0.77 | PIK3CA (0.44) | PIK3CADRD2DRD4DRD3DRD1 | |
| SCHEMBL3076808 | 0.77 | DRD2 (0.36) | PIK3CADRD2DRD4DRD3DRD1 | |
| SCHEMBL3075903 | 0.77 | EPHB3 (0.44) | PIK3CADRD2DRD4DRD3DRD1 | |
| SCHEMBL31595984 | 0.77 | PIK3CA (0.38) | PIK3CADRD2DRD4DRD3DRD1 | |
| SCHEMBL3073487 | 0.77 | PIK3CA (0.43) | PIK3CADRD2DRD4DRD3DRD1 | |
| SCHEMBL3065072 | 0.77 | HTR2A (0.39) | PIK3CADRD2DRD4DRD3DRD1 | |
| SCHEMBL31596020 | 0.75 | DRD2 (0.36) | DRD2DRD4DRD3DRD1HTR2A | |
| SCHEMBL3070335 | 0.74 | PIK3CA (0.50) | PIK3CAPIK3CDPIK3CB | |
| SCHEMBL3069691 | 0.73 | HTR2A (0.51) | PIK3CADRD2DRD4DRD3DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2176260-A1 | PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-04-21 | — | — | EP | claimed |
| WO-2009008748-A1 | PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-01-15 | — | — | WO | claimed |
| US-20100226881-A1 | PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-09-09 | — | — | US | disclosed |
| EP-2183239-A1 | SULFONAMIDES AS TRPM8 MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2010-05-12 | — | — | EP | disclosed |
| EP-2176260-A1 | PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009012430-A1 | SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-22 | — | — | WO | disclosed |
| WO-2009008748-A1 | PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100226881-A1 | PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY | TP53, PNPO, DPYD | PIK3CA 410/4885DRD2 4232/4885DRD4 4091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.